Session Details

U073 Markers of Risk, Not Pre-Melanomas: Case-Based Management of Dysplastic Nevi

Mon, Mar 22, 7:30 AM - 8:30 AM
1 CME Available Focus Session

DESCRIPTION

Despite recent evidence that suggests dysplastic nevi (DN) are not obligate precursors to melanoma but are markers of melanoma risk, management of dysplastic nevi remains controversial and variable across dermatologists. This session will use a case-based approach to review data-driven guidelines to walk through appropriate surgical and non-surgical management, ways to discuss the DN natural history and follow-up cadence with patient, and adjunct screening and detection tools. These cases represent practical, real-life scenarios and will be presented using an audience response system.

LEARNING OBJECTIVES

1.

Treat dysplastic nevi of all grades using data-driven guidelines

2.

Communicate the implications of a dysplastic nevus diagnosis effectively with a patient

3.

Develop a follow-up management plan for a patient with dysplastic nevi

SCHEDULE

7:30 AM

Management of Dysplastic Nevi

Suephy C. Chen, MD, FAAD

7:50 AM

Shared Decision Making for Management of Dysplastic Nevi

Elizabeth Gates Berry, MD, FAAD

8:10 AM

Optimizing Management for Patients with Dysplastic Nevi

Caroline C. Kim, MD, FAAD

DIRECTOR

Suephy C. Chen, MD, FAAD

Suephy C. Chen, MD, FAAD

Thomas Jefferson University, Jefferson Abington Hospital

SPEAKERS

Elizabeth Gates Berry, MD, FAAD

Elizabeth Gates Berry, MD, FAAD

Oregon Health & Science University; Portland VA Medical Center

Caroline C. Kim, MD, FAAD

Caroline C. Kim, MD, FAAD

Tufts Department of Dermatology and Newton-Wellesley Dermatology Associates

DISCLOSURES

Elizabeth Gates Berry, MD, FAAD

Merck & Co., Inc – Advisory Board(Fees); Orlucent – Investigator(Grants/Research Funding);

Suephy C. Chen, MD, FAAD

Sanofi Aventis – Other(Patent royalties or other compensation for Intellectual Property Rights); Syneos Health – Other(Patent royalties or other compensation for Intellectual Property Rights);

Caroline C. Kim, MD, FAAD

No financial relationships exist with ineligible companies.